Young Professionals Committee

Who We Are
The ADDF is proud to have the support of this fascinating mix of Young Professionals (ages 25-45) whose devotion to funding a drug cure for Alzheimer’s and dementia is vital. This committee of enthusiastic New Yorkers serves as ADDF ambassadors, building awareness of our mission through business associates, family and their social circle, and raising much-needed funds for Alzheimer’s drug discovery. The committee’s work gives young professionals the opportunity to develop leadership skills in a philanthropic environment and to use their time, talents, and contacts to strengthen the ADDF.

While the Young Professionals group is both educational and social in nature, our true goal is to build leadership amongst this age group, working with people committed to the cause of a drug cure for these devastating diseases. As it continues to grow, the Committee will decide on its level of involvement in ADDF activities.

Goals & Expectations

  • Young Professionals Committee members should be dedicated to the organization’s mission of accelerating drug discovery for Alzheimer’s disease and committed to using their skills and strengths to build up the organization.
  • Young Professionals Committee members should contribute to the committee through participation in bi-monthly meetings, soliciting donations, and organizing and executing fundraising strategies and events.
  • Young Professionals Committee members brainstorm new strategies and approaches for fundraising opportunities, marketing, outreach and planning.

Membership
The Young Professionals Committee is open to new members and encourages interested individuals to contact Allison Sawczyn at 212.901.8016 orĀ asawczyn@alzdiscovery.org.

1 out of 3 individuals will be affected by Alzheimer's Disease by the age of 80.

Donate Now

We're doing whatever it takes to find a cure for Alzheimer's Disease. But we can't do it without you. Please give generously today. Learn More

Apply for a Grant

ADDF invites scientists to apply for a grant through its Novel Approaches to Drug Discovery for Alzheimer's Disease research award program. Learn More